OXiGENE, Inc. entered a worldwide agreement to license Angiogene Pharmaceuticals’ vascular disrupting agent (VDA) program for neuroendocrine cancers, focused on carcinoid syndrome. OXiGENE plans to develop Zybrestat to treat carcinoid syndrome associated with metastatic cancer and neuroendocrine tumors. OXiGENE expects to conduct a Phase II study in persistent carcinoid syndrome, with the potential to advance to a registration clinical program.   “In-licensing this intellectual property an...